<DOC>
	<DOCNO>NCT02188706</DOCNO>
	<brief_summary>The goal clinical research study compare response rate patient receive decitabine alone , decitabine carboplatin , decitabine arsenic trioxide patient AML MDS .</brief_summary>
	<brief_title>A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin Decitabine/Arsenic Treatment Relapsed , Refractory , Elderly Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study one first 30 participant enrol , equal chance one 3 study group . If enroll first 30 participant enrol , high chance assign group well result . - If Group 1 , receive decitabine alone . - If Group 2 , receive decitabine carboplatin . - If Group 3 , receive decitabine arsenic trioxide . Study Drug Administration : Every 4 week study cycle . You receive decitabine vein 1 hour Days 1-5 cycle . If receive carboplatin , receive 1 hour Day 8 ( +/-2 day ) cycle . If receive arsenic trioxide , receive 1 hour Days 1-5 cycle Study Visits : Blood ( 1-2 teaspoon ) draw 1-2 time week Cycle 1 every 2-4 week routine test . If stable disease , blood drawn every 4-6 week . On Day 28 Cycle 3 ( +/- 3 day ) , bone marrow aspirate biopsy check status disease . After , bone marrow biopsies/aspirations doctor think need . If Group 3 , EKGs Day 1 cycle receive study drug . On Days 1 4 cycle , blood ( 1-2 teaspoon ) also draw routine test dose study drug . If take study , blood ( 1-2 teaspoon ) draw routine test . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug ( ) disease get bad , intolerable side effect occur , unable follow study direction . This investigational study . Arsenic trioxide FDA approve commercially available treatment APL . Decitabine FDA approve commercially available treatment MDS . Carboplatin FDA approve commercially available treatment solid tumor . The study drug study drug combination receive study consider investigational . Up 120 patient take part study . Up 20 patient enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Patients AML , relapse refractory standard therapy elderly patient AML ( age 65 ) . Patients AML young age 65 consider unfit conventional chemotherapy eligible . Patients de novo treat MDS CMML INT1 eligible . Patients may prior exposure azacitidine one cycle decitabine . Patients must chemotherapy 2 week prior enter study recover toxicity therapy ; A caveat case rapidly progressive disease . Hydroxyurea permit control elevate WBC prior treatment continue first 4 week therapy . Erythropoiesis stimulate agent ( ESAs ) GCSF allow therapy . ESAs , GCSF growth factor permit therapy . 2 . Performance 02 ( ECOG ) . 3 . Adequate cardiac function assess 2D ECHO ( NYHA cardiac IIIIV exclude ) . 4 . Pretreatment EKG 5 . Adequate end organ function creatinine &lt; /= 2mg/dL total bilirubin &lt; /= 2mg/dL , AST ALT &lt; /= = 2.5 X institutional ULN . 6 . Absence significant intercurrent illness uncontrolled heart failure , unstable angina , cardiac arrhythmia psychiatric illness precludes give informed consent . 7 . Signed informed consent 1 . Nursing pregnant female . Patients childbearing potential practice effective method contraception . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 2 . Current uncontrolled infection . 3 . Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement . 4 . Chronic kidney disease &gt; stage 3 . 5 . HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Relapsed refractory</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Arsenic Trioxide</keyword>
	<keyword>ATO</keyword>
	<keyword>Trisenox</keyword>
</DOC>